Our strategy

  • License GTU®-technology to licensees’ captive R&D projects
  • Seek collaborative R&D and license agreements with partners having their own proprietary antigens targeted at gene therapy and/or vaccines
  • Expand FIT’s own R&D portfolio to multiple areas